查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球子宫内膜异位症药物市场-2022-2029
市场调查报告书
商品编码
1143408

全球子宫内膜异位症药物市场-2022-2029

Global Endometriosis Drug Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 200 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概览

预计 2018 年子宫内膜异位症治疗市场的市场规模将达到 18.0778 亿美元，预计在 2022-2029 年的预测期内以 10.4% 的复合年增长率增长。

子宫内膜异位症是一种疼痛性疾病，其中与通常排列在子宫内的组织（子宫内膜）相似的组织在子宫外生长。子宫内膜异位症最常影响卵巢、输卵管和盆腔组织。子宫内膜异位症很少发生在盆腔器官区域之外。

市场动态

推动市场增长的主要因素是对这种疾病的认识提高、口服避孕药的普及以及由于诊断技术的改进导致子宫内膜异位症患者的增加。

随着子宫内膜异位症负担的增加，意识的提高和新产品的开发正在推动全球市场的增长。

根据世界卫生组织的数据，子宫内膜异位症影响全球约 10%（1.9 亿）的育龄妇女和女孩。此外，据英国 ENDOMETRIOSIS 统计，英国每 10 名育龄妇女中就有 1 名患有子宫内膜异位症，而不孕妇女的子宫内膜异位症患病率高达 30-50%，是美国第二常见的妇科疾病。 ，影响 150 万人。这与每年在治疗、失业和医疗费用方面花费英国经济 82 亿英镑的糖尿病患者人数大致相同。此外，提高诊断和治疗水平的努力也在推动全球市场。欧洲研究人员制定了新的子宫内膜异位症诊断和治疗指南，显着更新了管理该疾病的五个关键领域，包括诊断、治疗和復发。

提高对子宫内膜异位症认识的努力也有助于全球市场的增长。 2022 年 3 月 12 日，随着奥地利子宫内膜异位症协会 (EVA) 举办了第二次为期一天的免费子宫内膜异位症在线会议，世卫组织正在与民间社会和子宫内膜异位症宣传团体合作。我们合作并参与宣传和支持的努力。研究人员还在努力更好地了解这种疾病及其症状，以改善诊断和治疗。例如，新诊断方法的开发，例如 Ziwig SAS 于 2022 年 2 月 11 日推出的用于快速检测子宫内膜异位症的“Endotest”唾液测试，是无创、易于使用且存在于唾液中的。研究下一代 microRNA 测序，并运用人工智能产生的海量数据。

无效的药物治疗和低成功率正在抑制全球子宫内膜异位症药物市场的增长。

然而，药物治疗无效和成功率低是製约市场增长的主要因素。

COVID-19 影响分析

在 COVID-19 大流行期间，意识训练营被取消或推迟或转为在线模式，由于采取了社交距离等规定来控制病毒，因此减少了人口池。此外，大多数研究设施被关闭或降级，延长了研究项目。此外，由于难以进行定期妇科医生检查，大多数子宫内膜异位症患者未被发现，在大流行期间对全球市场产生负面影响。

细分分析

在预测期内（2022-2029），激素治疗有望对子宫内膜异位症药物市场产生较大影响

激素疗法将在 2021 年占据全球市场的最大份额，并且由于临床研究和新产品开发的增加，预计将在整个预测期内（2022-2029 年）占据主导地位。例如，clinicaltrials.gov 目前有四项干预试验调查激素治疗子宫内膜异位症。例如，由美国大学贝鲁特医学中心、维克森林大学健康科学学院赞助的一项试验评估地诺孕素与 GnRH-a 对接受体外受精的子宫内膜异位症女性的调理，预计结束日期为 2023 年 2 月 22 日。我们资助的生育力增强临床试验（EFFECT），预计将于 2022 年 12 月完成。此外，2021 年 5 月 26 日，美国食品药品监督管理局 (FDA) 批准 MYFEMBREE（relgolix 40 mg，雌二醇 1 mg，醋酸去甲肾上腺素 0.5 mg）作为首个每日一次的子宫内膜异位症治疗药物，正在进行中。

区域分析

预计北美将主导全球子宫内膜异位症药物市场。

北美将在 2021 年主导全球市场，由于该地区子宫内膜异位症的高发率，预计将在整个预测期间（2022-2029 年）占据主导地位。例如，根据约翰霍普金斯医学院的数据，子宫内膜异位症估计会影响 2-10% 的 25-40 岁的美国女性。根据女性健康办公室的数据，超过 11% 的美国 15 至 44 岁女性患有子宫内膜异位症。此外，在北美，许多提高对子宫内膜异位症认识的政府和非政府组织的存在有助于该地区在全球市场上的主导地位。此外，占据大部分市场份额的Pfizer Inc., Johnson & Johnson, Merck & Co., Inc., Eli Lilly and Company, AbbVie等主要市场参与者均位于美国，占比最大预测期内全球子宫内膜异位症药物的市场份额，确保了北美市场的主导地位。

竞争格局

全球子宫内膜异位症药物市场竞争激烈，可能是由于主导市场的大型药物管道。一些主要参与者包括 Eli Lilly and Company, Pfizer Inc., Bayer, AstraZeneca, Novartis AG, Merck & Co., Inc., Boehringer Ingelheim International GmbH, Johnson & Johnson Services, INC., AbbVie, GlaxoSmithKline plc. 。这些公司通过技术创新、产品发布、合作研究、收购和合作获得主要市场份额。例如，2022 年 8 月 16 日，GlaxoSmithKline plc.收购了 Affinivax, Inc.。此外，2021 年 12 月 22 日，Novartis AG将收购 Gyroscope Therapeutics。

  • AstraZeneca

    • 概述

    AstraZenecaplc 成立于 1999 年，总部位于英国剑桥。 AstraZeneca plc 是癌症、心血管、胃肠道、传染病、神经科学、呼吸和炎症领域的领先製药和生物技术公司。

    产品组合

    AstraZenecaplc 的子宫内膜异位症产品组合包括 ZOLADEX。

    全球子宫内膜异位症药物报告将提供大约 40 多个市场数据表、45+ 个数字和 200 页（大约）的区域。.

    内容

    第一章研究方法与范围

    • 调查方法
    • 调查目的和范围

    第 2 章市场定义和概述

    第 3 章执行摘要

    第 4 章市场动态

    • 市场影响因素
      • 驱动程序
        • 增加对子宫内膜异位症的负担和认识
        • 研发
      • 约束因素
        • 开发成本高
        • 无效的药物治疗
      • 商机
      • 影响分析

    第五章行业分析

    • 波特五力分析
    • 供应链分析
    • 监管分析
    • 管道分析
    • 流行病学分析

    第 6 章 COVID-19 分析

    • COVID-19 的市场分析
      • COVID-19 之前的市场情景
      • COVID-19 的当前市场情景
      • COVID-19 后或未来情景
    • COVID-19 期间的价格动态
    • 供需范围
    • 大流行期间与市场相关的政府举措
    • 製造商的战略举措
    • 总结

    第 7 章按类型

    • 腹膜浅表病变
    • 子宫内膜异位症
    • 深浸润性子宫内膜异位症
    • 其他

    第 8 章按治疗类型

    • 激素疗法
    • 疼痛管理
    • 其他

    第 9 章给药途径

    • 口语
    • 肠胃外
    • 其他

    第 10 章，最终用户

    • 医院和诊所
    • 居家护理
    • 其他

    第 11 章按地区划分

    • 北美
      • 美国
      • 加拿大
      • 墨西哥
    • 欧洲
      • 德国
      • 英国
      • 法国
      • 意大利
      • 西班牙
      • 其他欧洲
    • 南美洲
      • 巴西
      • 阿根廷
      • 其他南美洲
    • 亚太地区
      • 中国
      • 印度
      • 日本
      • 澳大利亚
      • 其他亚太地区
    • 中东和非洲

    第 12 章竞争格局

    • 主要发展和战略
    • 公司份额分析
    • 产品基准

    第 13 章公司简介

    • AstraZeneca
      • 公司简介
      • 产品组合和描述
      • 主要亮点
      • 财务摘要
    • Eli Lilly and Company
    • Pfizer Inc.
    • Bayer
    • Novartis AG
    • Merck & Co., Inc.
    • Boehringer Ingelheim International GmbH
    • Johnson & Johnson Services, INC.
    • AbbVie
    • GlaxoSmithKline plc.（*未详尽列出）

    第 14 章数据M

    简介目录
    Product Code: DMPH132

    Market Overview

    Endometriosis Drug Market is estimated to reach a market value of USD 1807.78 million by 2018 and the market is estimated to grow at a CAGR of 10.4% in the forecasted period 2022-2029.

    Endometriosis is a painful ailment in which tissue analogous to the tissue that usually lines the inside of the uterus (endometrium) grows outside the uterus. Endometriosis most commonly involves ovaries, fallopian tubes, and the tissue lining pelvis. Endometriosis is rarely encountered outside the area of the pelvic organs.

    Market Dynamics

    Increased awareness about the disease, growing trend in the adoption of the oral contraceptive pill, and increased incidents of endometriosis due to improved diagnostics techniques are some of the major factors driving the market's growth.

    With the increasing burden of endometriosis, awareness and new product developments drive global market growth.

    According to the WHO, Endometriosis affects roughly 10% (190 million) of reproductive age women and girls globally; also, as per the ENDOMETRIOSIS UK, 1 in 10 women of reproductive age in the UK suffer from endometriosis, and the prevalence of endometriosis in women with infertility be as high as to 30-50% making it the second most common gynecological condition in the UK affecting 1.5 million women, a similar number of those affected by diabetes which costs the UK economy £8.2bn a year in treatment, loss of work and healthcare costs. Moreover, the increased efforts to improve the diagnosis and treatment drive the global market. European researchers have created new guidelines for diagnosing and treating endometriosis and have significantly updated five key areas in managing the condition, including diagnosis, treatment, and recurrence, which will help patients and clinicians better understand and manage the condition.

    The rising efforts to spread awareness about endometriosis are also contributing to the global market growth; like the Endometriosis Association Austria (EVA) On 12 March 2022 hosted a free, full-day, online congress on endometriosis for the second time, WHO collaborated with civil society and endometriosis patient support groups to join the effort of spreading awareness and support. Researchers have also been working to understand the disease and its symptoms better to improve diagnosis and treatment. For instance, the development of a new diagnostic method like the Endotest saliva test for quickly detecting endometriosis by Ziwig SAS launched on 11 February 2022, which is a non-invasive and easy-to-use test and relies on Next-generation Sequencing of micro-RNA present in saliva and with the artificial intelligence to exercise the large amount of data generated.

    Ineffective drug therapies and poor success rates restrain the global endometriosis drug market growth.

    However, ineffective drug therapies and poor success rates are the major factors restraining the market's growth.

    COVID-19 Impact Analysis

    During the COVID-19 pandemic, the awareness camps were either canceled or postponed or switched to online mode, reducing the population pool as regulations such as social distancing was employed to contain the virus. Furthermore, most research facilities were shut down or working on a reduced force, which prolonged the research project. Moreover, regular gynecologist checkups were difficult, leaving most endometriosis patients undetected, negatively impacting the global market during the pandemic.

    Segment Analysis

    Hormone therapy is expected to have a greater grasp on the endometriosis drug market during the forecast period (2022-2029)

    Hormone therapy accounted for the largest share of the global market during 2021 and is expected to dominate throughout the forecast period (2022-2029) owing to the increasing clinical research and new product developments. For instance, as per clinicaltrials.gov, currently, 4 interventional trials are recruiting to study hormonal treatment for endometriosis, such as a study to evaluate the Dienogest versus GnRH-a pre-treatment in women with endometriosis undergoing IVF, sponsored by American University of Beirut Medical Center with an estimated study completion date of February 22, 2023, and a study of Elagolix for fertility enhancement clinical trial (EFFECT) financed by Wake Forest University Health Sciences and estimated to be finished by December 2022. Furthermore, the launch of new products such in May 26, 2021, the U.S. Food and Drug Administration (FDA) approved MYFEMBREE (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg), the first once-daily treatment for endometriosis.

    Geographical Analysis

    North America is expected to command dominating the global endometriosis drug market.

    North America dominated the global market in 2021 and is expected to dominate throughout the forecast period (2022-2029) owing to the high prevalence of endometriosis in this region. For instance, according to Johns Hopkins Medicine, endometriosis affects an estimated 2% to 10% of American women aged 25-40. Also, as per Office on Women's Health, more than 11% of American women between 15 and 44 are affected by endometriosis. Furthermore, the presence of many government and non-government organizations spreading awareness about endometriosis in North America contributes to the dominance of this region over the global market. Moreover, the key market players such as Pfizer Inc., Johnson & Johnson, Merck & Co., Inc., Eli Lilly and Company and AbbVie, holding a majority of the market share, are US based, ensuring the command of North America over the global endometriosis drug market during the forecast period.

    Competitive Landscape

    The global endometriosis drug market is competitive because of a large drug pipeline, which will probably dominate the market. Some key players are Eli Lilly and Company, Pfizer Inc., Bayer, AstraZeneca, Novartis AG, Merck & Co., Inc., Boehringer Ingelheim International GmbH, Johnson & Johnson Services, INC., AbbVie and GlaxoSmithKline plc. These players hold the major share of the market through innovations, product launches, collaborations, acquisitions, and performing alliances. For instance, in August 16, 2022, GSK acquired Affinivax, Inc. Also, in December 22, 2021, Novartis acquired Gyroscope Therapeutics.

    AstraZeneca plc

    Overview:

    AstraZeneca plc was founded in 1999 and is headquartered in Cambridge, UK. AstraZeneca plc is a leading pharmaceutical and biotechnology company dealing with oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation.

    Product Portfolio:

    The product portfolio of AstraZeneca plc for endometriosis drugs has ZOLADEX.

    The global endometriosis drug report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.

    Table of Contents

    1. Methodology and Scope

    • 1.1. Research Methodology
    • 1.2. Research Objective and Scope of the Report

    2. Market Definition and Overview

    3. Executive Summary

    4. Market Dynamics

    • 4.1. Market Impacting Factors
      • 4.1.1. Drivers
        • 4.1.1.1. The Increasing Burden of Endometriosis and Increasing Awareness
        • 4.1.1.2. Research and Development
      • 4.1.2. Restraints
        • 4.1.2.1. High Developmental Cost
        • 4.1.2.2. Ineffective Drug Therapies
      • 4.1.3. Opportunity
      • 4.1.4. Impact Analysis

    5. Industry Analysis

    • 5.1. Porter's Five Forces Analysis
    • 5.2. Supply Chain Analysis
    • 5.3. Regulatory Analysis
    • 5.4. Pipeline Analysis
    • 5.5. Epidemiological Analysis

    6. COVID-19 Analysis

    • 6.1. Analysis of Covid-19 on the Market
      • 6.1.1. Before COVID-19 Market Scenario
      • 6.1.2. Present COVID-19 Market Scenario
      • 6.1.3. After COVID-19 or Future Scenario
    • 6.2. Pricing Dynamics Amid Covid-19
    • 6.3. Demand-Supply Spectrum
    • 6.4. Government Initiatives Related to the Market During Pandemic
    • 6.5. Manufacturer's Strategic Initiatives
    • 6.6. Conclusion

    7. By Type

    • 7.1. Introduction
      • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
      • 7.1.2. Market Attractiveness Index, By Type
    • 7.2. Superficial Peritoneal Lesion
      • 7.2.1. Introduction
      • 7.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
    • 7.3. Endometrioma
    • 7.4. Deeply Infiltrating Endometriosis
    • 7.5. Others

    8. By Therapy Type

    • 8.1. Introduction
      • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy Type
      • 8.1.2. Market Attractiveness Index, By Therapy Type
    • 8.2. Hormonal Therapy
      • 8.2.1. Introduction
      • 8.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
    • 8.3. Pain Management
    • 8.4. Others

    9. By Route of Administration

    • 9.1. Introduction
      • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
      • 9.1.2. Market Attractiveness Index, By Route of Administration
    • 9.2. Oral
      • 9.2.1. Introduction
      • 9.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
    • 9.3. Parenteral
    • 9.4. Others

    10. By End User

    • 10.1. Introduction
      • 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User Segment
      • 10.1.2. Market Attractiveness Index, By End User Segment
    • 10.2. Hospitals And Clinics
      • 10.2.1. Introduction
      • 10.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
    • 10.3. Homecare
    • 10.4. Other

    11. By Region

    • 11.1. Introduction
      • 11.1.1. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
      • 11.1.2. Market Attractiveness Index, By Region
    • 11.2. North America
      • 11.2.1. Introduction
      • 11.2.2. Key Region-Specific Dynamics
      • 11.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
      • 11.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy Type
      • 11.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
      • 11.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
      • 11.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
        • 11.2.7.1. The U.S.
        • 11.2.7.2. Canada
        • 11.2.7.3. Mexico
    • 11.3. Europe
      • 11.3.1. Introduction
      • 11.3.2. Key Region-Specific Dynamics
      • 11.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
      • 11.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy Type
      • 11.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
      • 11.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
      • 11.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
        • 11.3.7.1. Germany
        • 11.3.7.2. The U.K.
        • 11.3.7.3. France
        • 11.3.7.4. Italy
        • 11.3.7.5. Spain
        • 11.3.7.6. Rest of Europe
    • 11.4. South America
      • 11.4.1. Introduction
      • 11.4.2. Key Region-Specific Dynamics
      • 11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
      • 11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy Type
      • 11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
      • 11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
      • 11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
        • 11.4.7.1. Brazil
        • 11.4.7.2. Argentina
        • 11.4.7.3. Rest of South America
    • 11.5. Asia Pacific
      • 11.5.1. Introduction
      • 11.5.2. Key Region-Specific Dynamics
      • 11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
      • 11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy Type
      • 11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
      • 11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
      • 11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
        • 11.5.7.1. China
        • 11.5.7.2. India
        • 11.5.7.3. Japan
        • 11.5.7.4. Australia
        • 11.5.7.5. Rest of Asia Pacific
    • 11.6. Middle East and Africa
      • 11.6.1. Introduction
      • 11.6.2. Key Region-Specific Dynamics
      • 11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
      • 11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy Type
      • 11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
      • 11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

    12. Competitive Landscape

    • 12.1. Key Developments and Strategies
    • 12.2. Company Share Analysis
    • 12.3. Product Benchmarking

    13. Company Profiles

    • 13.1. AstraZeneca
      • 13.1.1. Company Overview
      • 13.1.2. Product Portfolio and Description
      • 13.1.3. Key Highlights
      • 13.1.4. Financial Overview
    • 13.2. Eli Lilly and Company
    • 13.3. Pfizer Inc.
    • 13.4. Bayer
    • 13.5. Novartis AG
    • 13.6. Merck & Co., Inc.
    • 13.7. Boehringer Ingelheim International GmbH
    • 13.8. Johnson & Johnson Services, INC.
    • 13.9. AbbVie
    • 13.10. GlaxoSmithKline plc.(*LIST NOT EXHAUSTIVE)

    14. DataM Intelligence

    • 14.1. Appendix
    • 14.2. About Us and Services
    • 14.3. Contact Us